Matthew R. Plooster's Insider Trades & SAST Disclosures

Matthew R. Plooster's most recent trade in Zevra Therapeutics Inc was a trade of 49,200 Stock Option (right to buy) done . Disclosure was reported to the exchange on April 25, 2023.

Share

Note

This is a custom search result for pattern Matthew R. Plooster.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.

All Superstars

"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches "Balanced Fund" but not "Balanced Growth Fund" Balanced Fund: Use this format without quotation marks to search for all funds related to the term "Balanced Fund" The results may include "Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".

Stock	Client Name	Client Category	Action	Reported to Exchange	Quantity	Post Transaction Holding	Traded %	Avg. Price	Value	Security Type
Zevra Therapeutics Inc 52 week high	Matthew R. Plooster	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	25 Apr 2023	49,200	49,200	-		-	Stock Option (right to buy)
Zevra Therapeutics Inc 52 week high	Matthew R. Plooster	Director	Purchase of securities on an exchange or from another person at price $ 4.20 per share.	09 Mar 2023	11,000	18,500 (0%)	0%	4.2	46,148	Common Stock
Zevra Therapeutics Inc 52 week high	Matthew R. Plooster	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	28 Jun 2022	15,000	15,000	-		-	Stock Option (right to buy)
Zevra Therapeutics Inc 52 week high	Matthew R. Plooster	Director	Purchase of securities on an exchange or from another person at price $ 4.96 per share.	18 May 2022	3,051	7,161 (0%)	0%	5.0	15,133	Common Stock
Zevra Therapeutics Inc 52 week high	Matthew R. Plooster	Director	Purchase of securities on an exchange or from another person at price $ 4.95 per share.	18 May 2022	915	4,110 (0%)	0%	4.9	4,529	Common Stock
Zevra Therapeutics Inc 52 week high	Matthew R. Plooster	Director	Purchase of securities on an exchange or from another person at price $ 4.94 per share.	18 May 2022	695	3,195 (0%)	0%	4.9	3,433	Common Stock
Zevra Therapeutics Inc 52 week high	Matthew R. Plooster	Director	Purchase of securities on an exchange or from another person at price $ 4.97 per share.	18 May 2022	339	7,500 (0%)	0%	5.0	1,685	Common Stock
Zevra Therapeutics Inc 52 week high	Matthew R. Plooster	Director	Grant, award, or other acquisition of securities at price $ 8.44 per share.	01 Dec 2021	2,500	2,500 (0%)	0%	8.4	21,100	Common Stock
Zevra Therapeutics Inc 52 week high	Matthew R. Plooster	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	17 Jun 2021	15,000	15,000	-		-	Stock Option (right to buy)

*All Values are in $ Million

Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures

Data as reported to USA Exchanges

View All The Insider Trades